Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 Mar;36(2):101–107. doi: 10.1007/BF01754409

Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells

Avi Eisenthal 1,✉, Hanoch Kashtan 1, Micha Rabau 1, Vankatesh Ramakrishna 3, Samario Chaitchik 1, Yehuda Skornick 1
PMCID: PMC11038442  PMID: 8425207

Abstract

In the present study we evaluate the antitumor efficacy of a glycosylated molecule of interleukin-6 (IL-6), which was cloned and expressed in Chinese hamster ovary cells. When tested with two syngeneic murine tumors, the MC38 adenocarcinoma and the MCA106 fibrosarcoma, recombinant IL-6 (rIL-6) significantly reduced the number of day-3 established MC38 lung metastases, but had no effect on MCA106 lung metastases. A similar effect of rIL-6 was seen on day-3 MC38 liver metastases. The antitumor activity mediated by rIL-6 was achieved at doses of the cytokine ranging from 6 µg to 150 µg/day. There was no correlation between the responsiveness to rIL-6 of these two tumors and their susceptibility, in vitro, to a direct cytostatic effect of the cytokine or the increase in the expression of major histocompatibility complex (MHC) antigens after exposure to rIL-6. However, a correlation was seen between the antitumor response to rIL-6 and the initial number of tumor cells expressing MHC antigens. The possible role of MHC antigens expressed on tumor cells, the generation of MHC-restricted cytotoxic cells and the responsiveness to IL-6 are discussed.

Key words: Immunotherapy, Cytokines, ADCC, Recombinant interleukin-6, Eukaryotic cells

References

  • 1.Chen L, Mory Y, Zilberstein A, Revel M. Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2. Proc Natl Acad Sci USA. 1988;85:8037–8037. doi: 10.1073/pnas.85.21.8037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Chiu CP, Lee F. IL-6 is a differentiation factor for M1 and WEHI-3B myeloid leukemic cells. J Immunol. 1989;142:1909–1909. [PubMed] [Google Scholar]
  • 3.Eisenthal A, Rosenberg SA. The effect of various cytokines on the in-vitro induction of ADCC in murine cells: Enhancement of the IL-2 induced ADCC activity by IL-1. J Immunol. 1989;142:2307–2307. [PubMed] [Google Scholar]
  • 4.Eisenthal A, Rosenberg SA. Systemic induction of ADCC following administration of IL-2. Cancer Res. 1989;49:6953–6953. [PubMed] [Google Scholar]
  • 5.Eisenthal A, Shiloni E, Rosenberg SA. Characterization of interleukin-2 induced murine cells which exhibit ADCC activity. Cell Immunol. 1988;115:257–257. doi: 10.1016/0008-8749(88)90180-3. [DOI] [PubMed] [Google Scholar]
  • 6.Eisenthal A, Cameron RB, Rosenberg SA. Induction of ADCC in vivo by interferon alpha and its anti-tumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody. J Immunol. 1990;144:4463–4463. [PubMed] [Google Scholar]
  • 7.Fidler IJ, Heicappel R, Saiki I, Grutter G, Horisberger MA, Nuesch J. Direct antiproliferative affects of recombinant human interferon B/D hybrids on human tumor cell lines. Cancer Res. 1987;47:2020–2020. [PubMed] [Google Scholar]
  • 8.Gallagher G, Stimson WH, Findlay J, Al-Azzawi Interleukin-6 enhances the induction of human lymphokine-activated killer cells. Cancer Immunol Immunother. 1990;31:49–49. doi: 10.1007/BF01742495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon β2/B-cell stimulatory factory type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cell. Proc Natl Acad Sci USA. 1987;84:7251–7251. doi: 10.1073/pnas.84.20.7251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Gehan EA. Generalized Wilcoxon test for comparing arbitrarily single consored samples. Biometrica. 1965;52:203–203. [PubMed] [Google Scholar]
  • 11.German RD, Raulet DH. Characterization of a novel murine T cell-activating factor. J Immunol. 1987;138:1121–1121. [PubMed] [Google Scholar]
  • 12.Greiner JW, Guadagni F, Noguchi P, Pestka S, Colcher D, Fisher PB, Schlom J. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science. 1987;235:895–895. doi: 10.1126/science.3580039. [DOI] [PubMed] [Google Scholar]
  • 13.Hirano T, Yasukawa K, Hanada H, Taga T, Watanaba Y, Matsuda T, Kashiwamura SI, Nakajima K, Koyama K, Iwamatsu A, Tsunasawa S, Matsui H, Takahara Y, Taniguchi T, Kishimoto T. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986;324:73–73. doi: 10.1038/324073a0. [DOI] [PubMed] [Google Scholar]
  • 14.Kitahara M, Kishimoto S, Hirano T, Kishimoto T, Okada M. The in-vivo anti-tumor effect of human recombinant interleukin-6. Jpn J Cancer Res. 1990;81:1032–1032. doi: 10.1111/j.1349-7006.1990.tb03342.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kohlhelpp EA, Condon ME, Hamburger AW. Recombinant human interferon alpha enhancement or retinoic-acid-induced differentiation of HL-60 cells. Exp Hematol. 1987;15:414–414. [PubMed] [Google Scholar]
  • 16.Lafreniere R, Rosenberg SA. Adoptive immunotherapy of murine hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2 (RIL-2) can mediate the regression of both immunogenic and non-immunogenic sarcomas and an adenocarcinoma. J Immunol. 1985;135:4273–4273. [PubMed] [Google Scholar]
  • 17.Lotz M, Jirik F, Kabouridis P, Tsoukas C, Hirano T, Kishimoto T, Carson DA. B cell stimulating factor 2/interleukin-6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med. 1988;167:1253–1253. doi: 10.1084/jem.167.3.1253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Maekawa T, Metcalf D, Gearing DP. Enhanced suppression of human myeloid leukemia cell lines by combinations of IL-6, LIF, GM-CSF and G-CSF. Int J Cancer. 1990;45:353–353. doi: 10.1002/ijc.2910450224. [DOI] [PubMed] [Google Scholar]
  • 19.May LT, Ghrayeb J., Santhanam U, Tatter S, Sthoeger Z, Helfgott DC, Chiorazzi, Grieninger B, Sehgal PB. Synthesis and secretion of multiple forms of β-2 interferon/B-cell differentiation factor 2/hepatocyte stimulating factor by human fibroblasts and monocytes. J Biol Chem. 1988;263:7760–7760. [PubMed] [Google Scholar]
  • 20.Ming JE, Cernetti C, Steinman RM, Granelli-Piperono A. Interleukin-6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte condition medium. J Mol Cell Immunol. 1989;4:203–203. [PubMed] [Google Scholar]
  • 21.Miyaura C, Onozaki K, Akiyama Y, Taniyama T, Hirano T, Kishimoto T, Suda T. Recombinant human interleukin-6 (B-cell stimulating factor 2) is a potent inducer of differentiation of mouse leukemia cells (M1) FEBS Lett. 1988;234:17–17. doi: 10.1016/0014-5793(88)81293-6. [DOI] [PubMed] [Google Scholar]
  • 22.Mule JJ, Shu S, Schwarz SL, Rosenberg SA. Successful adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant IL-2. Science. 1984;225:1487–1487. doi: 10.1126/science.6332379. [DOI] [PubMed] [Google Scholar]
  • 23.Mule JJ, McIntosh JK, Jablons DM, Rosenberg SA. Antitumor activity of recombinant interleukin 6 in mice. J Exp Med. 1990;171:629–629. doi: 10.1084/jem.171.3.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Novick D, Eshhar Z, Revel M, Mory Y. Monoclonal antibodies for affinity purification of IL-6-IFN beta2 and for neutralization of HGF activity. Hybridoma. 1989;8:561–561. doi: 10.1089/hyb.1989.8.561. [DOI] [PubMed] [Google Scholar]
  • 25.Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 function as a killer helper factor in the in-vitro induction of cytotoxic T cells. J Immunol. 1988;141:1543–1543. [PubMed] [Google Scholar]
  • 26.Onozaki K, Akiyama Y, Okano A, Hirano T, Kishimoto T, Yoshizawa K, Taniyama T. Synergistic regulatory effects of interleukin 6 and interleukin 1 on the growth and differentiation of human myeloid leukemia cell lines. Cancer Res. 1989;49:3602–3602. [PubMed] [Google Scholar]
  • 27.Ortaldo JR, Mason LH, Mathieson BJ, Liang S, Flick DA, Herberman RB. Mediation of mouse natural cytotoxic activity by tumor necrosis factor. Nature. 1986;321:700–700. doi: 10.1038/321700a0. [DOI] [PubMed] [Google Scholar]
  • 28.Parker GA, Rosenberg SA. Serologic identification of multiple tumor-associated antigens on murine sarcoma. INCI. 1977;58:1303–1303. doi: 10.1093/jnci/58.5.1303. [DOI] [PubMed] [Google Scholar]
  • 29.Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF. Biological activity of recombinant human interleukin-2 produced inE. coli . Science. 1984;223:1412–1412. doi: 10.1126/science.6367046. [DOI] [PubMed] [Google Scholar]
  • 30.Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant IL-2. J Exp Med. 1985;161:1169–1169. doi: 10.1084/jem.161.5.1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Rosenberg SA, Spiess PJ, Lafreniere R. A new approach to adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233:1318–1318. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  • 32.Rosenstein M, Yron I, Kaufman Y, Rosenberg SA. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin-2. Cancer Res. 1984;44:1946–1946. [PubMed] [Google Scholar]
  • 33.Sachs DH, Cone JL. A murine B-cell alloantigen determined by gene(s) linked to the major histocompatibility complex. J Exp Med. 1973;138:1289–1289. doi: 10.1084/jem.138.6.1289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Sehgal PB, May LT, Tamm I, Vilcek J. Human β2 interferon and B-cell differentiation factor BSF-2 are identical. Science. 1987;235:731–731. doi: 10.1126/science.3492764. [DOI] [PubMed] [Google Scholar]
  • 35.Shiloni E, Eisenthal A, Sachs D, Rosenberg SA. Antibody dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin-2. J Immunol. 1987;138:1992–1992. [PubMed] [Google Scholar]
  • 36.Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor infiltrating lymphocytes expanded in recombinant interleukin-2. INCI. 1987;79:1067–1067. [PubMed] [Google Scholar]
  • 37.Takai Y, Wong GG, Clark SC, Burakoff SJ, Herrmann SH. B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J Immunol. 1988;140:508–508. [PubMed] [Google Scholar]
  • 38.Tamm I, Cardinale I, Krueger J, Murphy JS, May LT, Sehgal PB. Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J Exp Med. 1989;170:1649–1649. doi: 10.1084/jem.170.5.1649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Weber JS, Rosenberg SA. Modification of murine tumor major histocompatibility antigens by cytokines in-vivo and in-vitro. Cancer Res. 1988;48:5818–5818. [PubMed] [Google Scholar]
  • 40.Zilberstein A, Ruggieri R, Korn HJ, Revel M. Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growthstimulatory cytokines. EMBO J. 1986;5:2529–2529. doi: 10.1002/j.1460-2075.1986.tb04531.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES